Progestogens Used in Postmenopausal Hormone Therapy: Differences in Their Pharmacological Properties, Intracellular Actions, and Clinical Effects
Tóm tắt
Từ khóa
Tài liệu tham khảo
Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial, JAMA, 288, 321, 10.1001/jama.288.3.321
Anderson, 2004, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, JAMA, 291, 1701, 10.1001/jama.291.14.1701
North American Menopause Society, 2003, Role of progestogen in hormone therapy for postmenopausal women: position statement of the North American Menopause Society, Menopause, 10, 113, 10.1097/00042192-200310020-00003
Stanczyk, 2003, All progestins are not created equal, Steroids, 68, 879, 10.1016/j.steroids.2003.08.003
Henzl, 1978, Natural and synthetic female sex hormones, Reproductive endocrinology: physiology, pathophysiology and clinical management, 421
Kuhl, 2005, Pharmacology of estrogens and progestogens: influence of different routes of administration, Climacteric, 8, 3, 10.1080/13697130500148875
Stanczyk, 1990, Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids, Contraception, 42, 67, 10.1016/0010-7824(90)90093-B
Edgren, 1999, Nomenclature of the gonane progestins, Contraception, 60, 313, 10.1016/S0010-7824(99)00101-8
Stanczyk, 2000, Pharmacokinetics of progesterone administered orally and parenterally, Progestins and antiprogestins in clinical practice, 393
Kuhnz, 1997, In vivo conversion of norethesterone and norethisterone acetate to ethinyl estradiol in postmenopausal women, Contraception, 56, 379, 10.1016/S0010-7824(97)00174-1
Chu, 2007, Formation of ethinyl estradiol in women during treatment with norethindrone acetate, J Clin Endocrinol Metab, 92, 2205, 10.1210/jc.2007-0044
Hammond, 1982, Distribution and percentage of non-protein bound contraceptive steroids in human serum, J Steroid Biochem, 17, 375, 10.1016/0022-4731(82)90629-X
Kuhnz, 1990, Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum, J Steroid Biochem, 35, 313, 10.1016/0022-4731(90)90290-9
Westphal, 1974, Steroid-protein interactions
Simon, 1993, The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone, Fertil Steril, 60, 26, 10.1016/S0015-0282(16)56031-2
Victor, 1976, Pharmacokinetic observations on medroxyprogesterone acetate administered orally and intravaginally, Contraception, 14, 319, 10.1016/0010-7824(76)90099-8
Farinha, 2000, Improved bioavailability of a micronized megestrol acetate tablet formulation in humans, Drug Dev Ind Pharm, 26, 567, 10.1081/DDC-100101270
Kuhnz, 1993, Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles, Contraception, 48, 557, 10.1016/0010-7824(93)90118-Q
Kuhl, 1990, Pharmacokinetics of oestrogens and progestogens, Maturitas, 12, 171, 10.1016/0378-5122(90)90003-O
Lin, 1998, Determination of medrogestone in plasma by high-performance liquid chromatography, J Chromatogr B Biomed Sci Appl, 714, 263, 10.1016/S0378-4347(98)00223-0
Mueck, 2011, Nomegestrol acetate, a novel progestogen for oral contraception, Steroids, 76, 531, 10.1016/j.steroids.2011.02.002
Back, 1978, Kinetics of norethindrone in women. II. Single-dose kinetics, Clin Pharmacol Ther, 24, 448, 10.1002/cpt1978244448
Back, 1981, The pharmacokinetics of levonorgestrel and ethynylestradiol in women: studies with Ovran and Ovranette, Contraception, 23, 229, 10.1016/0010-7824(81)90045-7
Bergink, 1990, Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin, Am J Obstet Gynecol, 163, 2132, 10.1016/0002-9378(90)90553-J
Back, 1987, Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel, Contraception, 35, 619, 10.1016/S0010-7824(87)80021-5
Orme, 1991, The pharmacokinetics of ethinylestradiol in the presence and absence of gestodene and desogestrel, Contraception, 43, 305, 10.1016/0010-7824(91)90069-R
Täuber, 1989, Single dose pharmacokinetics of gestodene in women after intravenous and oral administration, Contraception, 40, 461, 10.1016/0010-7824(89)90053-X
Oettel, 1995, A 19-norprogestin without a 17α-ethinyl group. II. Dienogest from a pharmacokinetic point of view, Drugs Today, 31, 499
Blode, 2000, A l-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers, Eur J Contracept Reprod Health Care, 5, 256, 10.1080/13625180008500407
Krattenmacher, 2000, Drospirenone: pharmacology and pharmacokinetics of a unique progestogen, Contraception, 62, 29, 10.1016/S0010-7824(00)00133-5
Nillius, 1971, Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone, Am J Obstet Gynecol, 110, 470, 10.1016/0002-9378(71)90686-7
Miles, 1994, Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study, Fertil Steril, 62, 485, 10.1016/S0015-0282(16)56935-0
Stanczyk, 2005, Percutaneous administration of progesterone: blood levels and endometrial protection, Menopause, 12, 232, 10.1097/00042192-200512020-00019
Leonetti, 2003, Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium, Fertil Steril, 79, 221, 10.1016/S0015-0282(02)04542-9
Wren, 2000, Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women, Climacteric, 3, 155, 10.1080/13697130008500109
Product insert, 2007, Climara Pro
Harrison, 2007, Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations, Drug Dev Ind Pharm, 33, 373, 10.1080/03639040600815178
Product insert, 2006, CombiPatch
Lu, 2006, International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors, Pharmacol Rev, 58, 782, 10.1124/pr.58.4.9
Africander, 2011, Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception, Steroids, 76, 636, 10.1016/j.steroids.2011.03.001
Moore, 2012, Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells, Mol Cell Endocrinol, 357, 60, 10.1016/j.mce.2011.09.019
Lavery, 2005, Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations, Biochem J, 391, 449, 10.1042/BJ20050872
Griekspoor, 2007, Visualizing the action of steroid hormone receptors in living cells, Nucl Recept Signal, 5, e003, 10.1621/nrs.05003
Tang, 1998, The DNA-binding and τ2 transactivation domains of the rat glucocorticoid receptor constitute a nuclear matrix-targeting signal, Mol Endocrinol, 12, 1420
Bourguet, 2000, Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications, Trends Pharmacol Sci, 21, 381, 10.1016/S0165-6147(00)01548-0
Beato, 2000, Steroid hormone receptors: an update, Hum Reprod Update, 6, 225, 10.1093/humupd/6.3.225
Weatherman, 1999, Nuclear-receptor ligands and ligand-binding domains, Ann Rev Biochem, 68, 559, 10.1146/annurev.biochem.68.1.559
Tanenbaum, 1998, Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains, Proc Natl Acad Sci USA, 95, 5998, 10.1073/pnas.95.11.5998
Williams, 1998, Atomic structure of progesterone complexed with its receptor, Nature, 393, 392, 10.1038/30775
Fuller, 1991, The steroid receptor superfamily: mechanisms of diversity, FASEB J, 5, 3092, 10.1096/fasebj.5.15.1743440
Evans, 1988, The steroid and thyroid hormone receptor superfamily, Science, 240, 889, 10.1126/science.3283939
Loosfelt, 1986, Cloning and sequence analysis of rabbit progesterone-receptor complementary DNA, Proc Natl Acad Sci USA, 83, 9045, 10.1073/pnas.83.23.9045
Bledsoe, 2002, Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition, Cell, 110, 93, 10.1016/S0092-8674(02)00817-6
Kastner, 1990, Transient expression of human and chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms, J Biol Chem, 265, 12163, 10.1016/S0021-9258(19)38326-7
Sartorius, 1994, A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform, Mol Endocrinol, 8, 1347
Wen, 1994, The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells, Mol Cell Biol, 14, 8356, 10.1128/MCB.14.12.8356
Giangrande, 2000, The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding, Mol Cell Biol, 20, 3102, 10.1128/MCB.20.9.3102-3115.2000
Oakley, 2011, Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids, J Biol Chem, 286, 3177, 10.1074/jbc.R110.179325
Zhou, 2005, The human glucocorticoid receptor: one gene, multiple proteins and diverse responses, Steroids, 70, 407, 10.1016/j.steroids.2005.02.006
Mangal, 1997, Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle, J Steroid Biochem Mol Biol, 63, 195, 10.1016/S0960-0760(97)00119-2
Soyal, 2005, Cre-mediated recombination in cell lineages that express the progesterone receptor, Genesis, 41, 58, 10.1002/gene.20098
Shyamala, 1990, Developmental regulation of murine mammary progesterone receptor gene expression, Endocrinology, 126, 2882, 10.1210/endo-126-6-2882
Mulac-Jericevic, 2004, Reproductive tissue selective actions of progesterone receptors, Reproduction, 128, 139, 10.1530/rep.1.00189
Conneely, 2002, Reproductive functions of progesterone receptors, Recent Prog Horm Res, 57, 339, 10.1210/rp.57.1.339
Khan, 2011, p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization, Mol Endocrinol, 25, 1710, 10.1210/me.2011-1042
Mesiano, 2011, Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing?, Reprod Sci, 18, 6, 10.1177/1933719110382922
Courtin, 2012, Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells, Breast Cancer Res Treat, 131, 49, 10.1007/s10549-011-1394-5
Krozowski, 1983, Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity, Proc Natl Acad Sci USA, 80, 6056, 10.1073/pnas.80.19.6056
de Kloet, 2000, Brain mineralocorticoid receptors and centrally regulated functions, Kidney Int, 57, 1329, 10.1046/j.1523-1755.2000.00971.x
Funder, 2004, Aldosterone, mineralocorticoid receptors and vascular inflammation, Mol Cell Endocrinol, 217, 263, 10.1016/j.mce.2003.10.054
Koubovec, 2005, Synthetic progestogens used in HRT have different glucocorticoid agonist properties, Mol Cell Endocrinol, 242, 23, 10.1016/j.mce.2005.07.001
Philibert, 1999, The pharmacological profile of a novel norpregnane progestin (trimegestone), Gynecol Endocrinol, 13, 316, 10.3109/09513599909167574
Phillips, 1990, Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins, Contraception, 41, 399, 10.1016/0010-7824(90)90039-X
Juchem, 1993, Receptor binding of norgestimate: a new orally active synthetic progestational compound, Contraception, 47, 283, 10.1016/0010-7824(93)90044-8
Bamberger, 1999, Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes, J Clin Endocrinol Metab, 84, 4055
Bergink, 1983, Binding of progestagens to receptor proteins in MCF-7 cells, J Steroid Biochem, 19, 1563, 10.1016/0022-4731(83)90371-0
Deckers, 2000, Influence of the substitution of 11-methylene, Δ15, and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals, J Steroid Biochem Mol Biol, 74, 83, 10.1016/S0960-0760(00)00093-5
Chávez, 1985, Stereospecificity of the intracellular binding of norethisterone and its A-ring reduced metabolites, J Steroid Biochem, 22, 121, 10.1016/0022-4731(85)90151-7
Teulings, 1980, Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer, Cancer Res, 40, 2557
Schoonen, 2000, Hormonal properties of norethisterone, 7α-methyl-norethisterone and their derivatives, J Steroid Biochem Mol Biol, 74, 213, 10.1016/S0960-0760(00)00125-4
Kemppainen, 1999, Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone, Mol Endocrinol, 13, 440, 10.1210/mend.13.3.0255
Pérez-Palacios, 1981, Mechanism of action of contraceptive synthetic progestogens, J Steroid Biochem, 15, 125, 10.1016/0022-4731(81)90266-1
Hackenberg, 1993, Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor, Breast Cancer Res Treat, 25, 217, 10.1007/BF00689836
Bentel, 1999, Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells, Mol Cell Endocrinol, 154, 11, 10.1016/S0303-7207(99)00109-4
Schindler, 2003, Classification and pharmacology of progestogens, Maturitas, 46, S7, 10.1016/j.maturitas.2003.09.014
Sitruk-Ware, 2004, Pharmacological profile of progestogens, Maturitas, 47, 277, 10.1016/j.maturitas.2004.01.001
Fotherby, 1990, Interactions with oral contraceptives, Am J Obstet Gynecol, 163, 2153, 10.1016/0002-9378(90)90556-M
Fuhrmann, 1996, The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential, Contraception, 54, 243, 10.1016/S0010-7824(96)00195-3
Wambach, 1979, Interaction of synthetic progestagens with renal mineralocorticoid receptors, Acta Endocrinol (Copenh), 92, 560, 10.1530/acta.0.0920560
Rafestin-Oblin, 1992, Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp90 release from mineralocorticosteroid receptor, J Steroid Biochem Mol Biol, 41, 815, 10.1016/0960-0760(92)90430-Q
Quinkler, 2002, Difference of in vivo and in vitro antimineralocorticoid potency of progesterone, Endocr Res, 28, 465, 10.1081/ERC-120016824
Genazzani, 2007, Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8–9, 2007, Gynecol Endocrinol, 23, 436, 10.1080/09513590701577869
Winneker, 2003, The preclinical biology of a new potent and selective progestin: trimegestone, Steroids, 68, 915, 10.1016/S0039-128X(03)00142-9
Elger, 2003, Conception and pharmacodynamic profile of drospirenone, Steroids, 68, 891, 10.1016/j.steroids.2003.08.008
Sasagawa, 2008, Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile, Steroids, 73, 222, 10.1016/j.steroids.2007.10.003
Koubovec, 2004, Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells, Mol Cell Endocrinol, 221, 75, 10.1016/j.mce.2004.03.006
Ronacher, 2009, Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction, Mol Cell Endocrinol, 299, 219, 10.1016/j.mce.2008.10.008
Kontula, 1983, Binding of progestogens to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes, Biochem Pharmacol, 32, 1511, 10.1016/0006-2952(83)90474-4
Fuhrmann, 1995, Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays, Contraception, 51, 45, 10.1016/0010-7824(94)00003-F
Edgren, 1994, Issues in animal pharmacology, Pharmacology of the contraceptive steroids, 81
Bray, 2005, Quantitative analysis of gene regulation by seven clinically relevant progestogens suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells, J Steroid Biochem Mol Biol, 97, 328, 10.1016/j.jsbmb.2005.06.032
Ghatge, 2005, The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells, Breast Cancer Res, 7, R1036, 10.1186/bcr1340
Hyder, 1998, Progestin regulation of vascular endothelial growth factor in human breast cancer cells, Cancer Res, 58, 392
Mueller, 2003, Progestogens activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells, Fertil Steril, 79, 386, 10.1016/S0015-0282(02)04577-6
Fu, 2008, Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion, BMC Cancer, 8, 166, 10.1186/1471-2407-8-166
Lello, 2010, Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy, Drugs, 70, 541, 10.2165/11532130-000000000-00000
van Diepen, 2011, Nomegestrol acetate: steroid receptor transactivation profile in Chinese hamster ovary cells and ovulation inhibition in rat and monkey, Contraception, 84, 199, 10.1016/j.contraception.2010.11.017
Greenblatt, 1958, A new test of efficacy of progestational compounds, Ann NY Acad Sci, 71, 717, 10.1111/j.1749-6632.1958.tb46801.x
Swyer, 1968, Clinical assessment of relative potency of progestogens, J Reprod Fertil Suppl, 5, 63
Dorflinger, 1985, Relative potency of progestins used in oral contraceptives, Contraception, 31, 557, 10.1016/0010-7824(85)90056-3
Whitehead, 1981, Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium, N Engl J Med, 305, 1599, 10.1056/NEJM198112313052701
Whitehead, 1982, Effects of various types and dosages of progestins on the postmenopausal endometrium, J Reprod Med, 27, 539
Lane, 1983, Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium, Br Med J (Clin Res Ed), 287, 1241, 10.1136/bmj.287.6401.1241
Whitehead, 1983, Avoidance of endometrial hyperstimulation in estrogen-treated postmenopausal women, Semin Reprod Endocrinol, 1, 41, 10.1055/s-2007-1022574
Whitehead, 1983, The use of progestins and progesterone in the treatment of climacteric and postmenopausal symptoms, Progesterone and progestins, 277
Lane, 1986, Effects of dydrogesterone on the oestrogenized postmenopausal endometrium, Br J Obstet Gynaecol, 93, 55, 10.1111/j.1471-0528.1986.tb07814.x
Lane, 1986, Is Provera the ideal progestin for addition to postmenopausal estrogen therapy?, Fertil Steril, 45, 345, 10.1016/S0015-0282(16)49215-0
King, 1986, Assessment of the potency of orally administered progestins in women, Fertil Steril, 46, 1062, 10.1016/S0015-0282(16)49880-8
Vicent, 2010, Role of kinases and chromatin remodeling in progesterone signaling to chromatin, Mol Endocrinol, 24, 2088, 10.1210/me.2010-0027
Biddie, 2010, Genome-wide mechanisms of nuclear receptor action, Trends Endocrinol Metab, 21, 3, 10.1016/j.tem.2009.08.006
Leslie, 2005, Progesterone receptor isoform identification and subcellular localization in endometrial cancer, Gynecol Oncol, 96, 32, 10.1016/j.ygyno.2004.09.057
Lim, 1999, Differential localization and activity of the A- and B-forms of the human progesterone receptor using green fluorescent protein chimeras, Mol Endocrinol, 13, 366, 10.1210/mend.13.3.0247
Pratt, 1997, Steroid receptor interactions with heat shock protein and immunophilin chaperones, Endocr Rev, 18, 306
Hammes, 2007, Extranuclear steroid receptors: nature and actions, Endocr Rev, 28, 726, 10.1210/er.2007-0022
Perissi, 2005, Controlling nuclear receptors: the circular logic of cofactor cycles, Nat Rev Mol Cell Biol, 6, 542, 10.1038/nrm1680
Ballaré, 2003, Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells, Mol Cell Biol, 23, 1994, 10.1128/MCB.23.6.1994-2008.2003
Surjit, 2011, Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor, Cell, 145, 224, 10.1016/j.cell.2011.03.027
Kassel, 2007, Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects, Mol Cell Endocrinol, 275, 13, 10.1016/j.mce.2007.07.003
De Bosscher, 2009, Minireview: latest perspectives on antiinflammatory actions of glucocorticoids, Mol Endocrinol, 23, 281, 10.1210/me.2008-0283
De Bosscher, 2003, The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression, Endocr Rev, 24, 488, 10.1210/er.2002-0006
Revollo, 2009, Mechanisms generating diversity in glucocorticoid receptor signaling, Ann NY Acad Sci, 1179, 167, 10.1111/j.1749-6632.2009.04986.x
Kobayashi, 2010, Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer, Mol Endocrinol, 24, 2292, 10.1210/me.2010-0289
McKay, 1999, Molecular control of immune/inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signaling pathways, Endocr Rev, 20, 435
Kalkhoven, 1996, Negative interaction between the RelA(p65) subunit of NF-κB and the progesterone receptor, J Biol Chem, 271, 6217, 10.1074/jbc.271.11.6217
Palvimo, 1996, Mutual transcriptional interference between RelA and androgen receptor, J Biol Chem, 271, 24151, 10.1074/jbc.271.39.24151
Bellido, 1995, Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor, J Clin Invest, 95, 2886, 10.1172/JCI117995
Liden, 1997, A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation, J Biol Chem, 272, 21467, 10.1074/jbc.272.34.21467
Faivre, 2008, Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors, Mol Endocrinol, 22, 823, 10.1210/me.2007-0437
Faivre, 2007, Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells, Mol Cell Biol, 27, 466, 10.1128/MCB.01539-06
Goldhar, 2011, Progesterone induces expression of the prolactin receptor gene through cooperative action of Sp1 and C/EBP, Mol Cell Endocrinol, 335, 148, 10.1016/j.mce.2011.01.004
Nettles, 2005, Ligand control of coregulator recruitment to nuclear receptors, Annu Rev Physiol, 67, 309, 10.1146/annurev.physiol.66.032802.154710
McKenna, 1999, Nuclear receptor coregulators: cellular and molecular biology, Endocr Rev, 20, 321
Heinlein, 2002, Androgen receptor (AR) coregulators: an overview, Endocr Rev, 23, 175, 10.1210/edrv.23.2.0460
Reddy, 2009, Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation, Genome Res, 19, 2163, 10.1101/gr.097022.109
Hakim, 2010, 3D shortcuts to gene regulation, Curr Opin Cell Biol, 22, 305, 10.1016/j.ceb.2010.04.005
Xi, 2007, Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome, PLoS Genet, 3, e136, 10.1371/journal.pgen.0030136
Heintzman, 2009, Histone modifications at human enhancers reflect global cell-type-specific gene expression, Nature, 459, 108, 10.1038/nature07829
Santos, 2011, Negative regulation by nuclear receptors: a plethora of mechanisms, Trends Endocrinol Metab, 22, 87, 10.1016/j.tem.2010.11.004
Hu, 2008, Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules, Proc Natl Acad Sci USA, 105, 19199, 10.1073/pnas.0810634105
Beral, 2003, Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet, 362, 419, 10.1016/S0140-6736(03)14596-5
Kaunitz, 2006, Hormone therapy and breast cancer risk: trumping fear with facts, Menopause, 13, 160, 10.1097/01.gme.0000196814.41871.ff
Colditz, 2005, Estrogen, estrogen plus progestin therapy, and risk of breast cancer, Clin Cancer Res, 11, 909s, 10.1158/1078-0432.909s.11.2
Rosano, 2001, Comparative cardiovascular effects of different progestogens in menopause, Int J Fertil Womens Med, 46, 248
Sitruk-Ware, 2000, Progestins and cardiovascular risk markers, Steroids, 65, 651, 10.1016/S0039-128X(00)00174-4
Brunelli, 1996, Hormone replacement therapy affects various immune cell subsets and natural cytotoxicity, Gynecol Obstet Invest, 41, 128, 10.1159/000292057
Malarkey, 1997, Differential effects of estrogen and medroxyprogesterone on basal and stress-induced growth hormone release, IGF-1 levels, and cellular immunity in postmenopausal women, Endocrine, 7, 227, 10.1007/BF02778145
Wakatsuki, 2002, Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen, Circulation, 105, 1436, 10.1161/hc1202.105945
Stopińska-Głuszak, 2006, Effect of estrogen/progesterone hormone replacement therapy on natural killer cell cytotoxicity and immunoregulatory cytokine release by peripheral blood mononuclear cells of postmenopausal women, J Reprod Immunol, 69, 65, 10.1016/j.jri.2005.07.006
Ohkura, 1995, Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports, Dementia, 6, 99
Shumaker, 2003, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA, 289, 2651, 10.1001/jama.289.20.2651
Valdivia, 2004, Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women, Fertil Steril, 81, 617, 10.1016/j.fertnstert.2003.07.041
Odmark, 2004, Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being, Gynecol Endocrinol, 18, 305, 10.1080/09513590410001667265
Oelkers, 2004, Drospirenone, a progestogen with antimineralocorticoid properties: a short review, Mol Cell Endocrinol, 217, 255, 10.1016/j.mce.2003.10.030
Liu, 2010, Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo, Endocrinology, 151, 5782, 10.1210/en.2010-0005
Zhao, 2002, Long-term progestin treatment inhibits RANTES (regulated on activation, normal T cell expressed and secreted) gene expression in human endometrial stromal cells, J Clin Endocrinol Metab, 87, 2514, 10.1210/jcem.87.6.8526
Ramhorst, 2006, Induction of maternal tolerance to fetalalloantigens by RANTES production, Am J Reprod Immunol, 56, 302, 10.1111/j.1600-0897.2006.00430.x
Tatsumi, 2002, Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestogens, Maturitas, 42, 287, 10.1016/S0378-5122(02)00157-3
Yasa, 2005, Vasoprotective effects of nitric oxide in atherosclerosis, FABAD J Pharm Sci, 30, 41
Simoncini, 2004, Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells, Endocrinology, 145, 5745, 10.1210/en.2004-0510
Simoncini, 2007, Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels, Gynecol Endocrinol, 23, 9, 10.1080/09513590701585094
Irwin, 2011, Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function, Endocrinology, 152, 556, 10.1210/en.2010-1061
Muhn, 1995, Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity, Ann NY Acad Sci, 761, 311, 10.1111/j.1749-6632.1995.tb31386.x
Zhang, 2000, In vitro characterization of trimegestone: a new potent and selective progestin, Steroids, 65, 637, 10.1016/S0039-128X(00)00120-3
García-Becerra, 2004, Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestogens, J Steroid Biochem Mol Biol, 91, 21, 10.1016/j.jsbmb.2004.02.003
Africander, 2011, Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract, Contraception, 84, 423, 10.1016/j.contraception.2011.06.006
Birrell, 2007, Disruption of androgen receptor signaling by synthetic progestogens may increase risk of developing breast cancer, FASEB J, 21, 2285, 10.1096/fj.06-7518com
Hadley, 2011, Differential nuclear localisation and promoter occupancy play a role in glucocorticoid receptor ligand-specific transcriptional responses, Steroids, 76, 1176, 10.1016/j.steroids.2011.05.007
Ishida, 2002, Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis, Osteoporos Int, 13, 601, 10.1007/s001980200080
Ishida, 2008, Effect of progestogens with different glucocorticoid activity on bone metabolism, Clin Endocrinol (Oxf), 68, 423, 10.1111/j.1365-2265.2007.03059.x
Kurebayashi, 2003, Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2, Thyroid, 13, 249, 10.1089/105072503321582042
Zhao, 2003, Receptor density dictates the behavior of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression, Int Immunopharmacol, 3, 1803, 10.1016/j.intimp.2003.08.005
Thomas, 2006, Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate α-ENaC and sgk1 expression in renal collecting duct epithelia, Am J Physiol Renal Physiol, 290, F306, 10.1152/ajprenal.00062.2005
Ouatas, 2003, Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds, Clin Cancer Res, 9, 3763
Zerr-Fouineau, 2007, Progestogens overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors, FASEB J, 21, 265, 10.1096/fj.06-6840com
Spangelo, 1995, Role of the cytokines in the neuroendocrine-immune system axis, Front Neuroendocrinol, 16, 1, 10.1006/frne.1995.1001
Galon, 2002, Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells, FASEB J, 16, 61, 10.1096/fj.01-0245com
Herkert, 2001, Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor, Circulation, 104, 2826, 10.1161/hc4801.099737
Moutsatsou, 2008, The glucocorticoid receptor signalling in breast cancer, J Cell Mol Med, 12, 145, 10.1111/j.1582-4934.2007.00177.x
Courtin, 2012, Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells, Breast Cancer Res Treat, 131, 49, 10.1007/s10549-011-1394-5
Wan, 2002, Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells, Mol Endocrinol, 16, 1204, 10.1210/mend.16.6.0848
Oelkers, 1996, Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure, Steroids, 61, 166, 10.1016/0039-128X(96)00007-4
Rylance, 1985, Natural progesterone and antihypertensive action, Br Med J (Clin Res Ed), 290, 13, 10.1136/bmj.290.6461.13
Quinkler, 2002, Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor, Eur J Endocrinol, 146, 789, 10.1530/eje.0.1460789
Oelkers, 2005, Drospirenone in combination with estrogens: for contraception and hormone replacement therapy, Climacteric, 8, 19, 10.1080/13697130500330341
Arias-Loza, 2009, Differential effects of 17β-estradiol and of synthetic progestogens on aldosterone-salt-induced kidney disease, Toxicol Pathol, 37, 969, 10.1177/0192623309350475
Seeger, 2009, Effects of drospirenone on cardiovascular markers in human aortic endothelial cells, Climacteric, 12, 80, 10.1080/13697130802403994
Di Carlo, 1983, Changes in the binding of oestradiol to uterine oestrogen receptors induced by some progesterone and 19-nor-testosterone derivatives, J Endocrinol, 98, 385, 10.1677/joe.0.0980385
Markiewicz, 1994, Estrogenic and progestagenic activities coexisting in steroidal drugs: quantitative evaluation by in vitro bioassays with human cells, J Steroid Biochem Mol Biol, 48, 89, 10.1016/0960-0760(94)90254-2
Mendoza-Rodríguez, 1999, Variations of progesterone receptor and c-fos gene expression in the rat uterus after treatment with norethisterone and its A-ring reduced metabolites, Contraception, 59, 339, 10.1016/S0010-7824(99)00039-6
Larrea, 2001, A-ring reduced metabolites of 19-nor synthetic progestogens as subtype selective agonists for ERα, Endocrinology, 142, 3791, 10.1210/endo.142.9.8401
Stellato, 2004, Post-transcriptional and nongenomic effects of glucocorticoids, Proc Am Thorac Soc, 1, 255, 10.1513/pats.200402-015MS
Wierman, 2007, Sex steroid effects at target tissues: mechanisms of action, Adv Physiol Educ, 31, 26, 10.1152/advan.00086.2006
Grossmann, 2009, New aspects of rapid aldosterone signaling, Mol Cell Endocrinol, 308, 53, 10.1016/j.mce.2009.02.005
Zhu, 2008, Candidates for membrane progestin receptors: past approaches and future challenges, Comp Biochem Physiol C Toxicol Pharmacol, 148, 381, 10.1016/j.cbpc.2008.05.019
Nilsen, 2003, Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling, Proc Natl Acad Sci USA, 100, 10506, 10.1073/pnas.1334098100
Boonyaratanakornkit, 2008, The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression, Steroids, 73, 922, 10.1016/j.steroids.2008.01.010
Hagan, 2012, Role of phosphorylation in progesterone receptor signaling and specificity, Mol Cell Endocrinol, 357, 43, 10.1016/j.mce.2011.09.017
Proietti, 2005, Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells, Mol Cell Biol, 25, 4826, 10.1128/MCB.25.12.4826-4840.2005
Béguelin, 2010, Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3, Mol Cell Biol, 30, 5456, 10.1128/MCB.00012-10
Thomas, 2008, Characteristics of membrane progestin receptor α (mPRα) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions, Front Neuroendocrinol, 29, 292, 10.1016/j.yfrne.2008.01.001
Thomas, 2007, Steroid and G protein binding characteristics of the sea trout and human progestin membrane receptor α subtypes and their evolutionary origins, Endocrinology, 148, 705, 10.1210/en.2006-0974
Dosiou, 2008, Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone, J Endocrinol, 196, 67, 10.1677/JOE-07-0317
Saitoh, 2005, Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-κB cascade in human breast cancer cells, Endocrinology, 146, 4917, 10.1210/en.2004-1535
Limbourg, 2002, Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids, J Clin Invest, 110, 1729, 10.1172/JCI0215481
Walker, 2003, Nongenomic actions of androgen in Sertoli cells, Curr Top Dev Biol, 56, 25, 10.1016/S0070-2153(03)01006-8
Rarick, 2007, United States regulatory considerations for intrauterine progestins for hormone replacement therapy, Contraception, 75, S140, 10.1016/j.contraception.2006.12.011
Genant, 1997, Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group, Arch Intern Med, 157, 2609, 10.1001/archinte.1997.00440430091011
Ettinger, 2004, Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial, Obstet Gynecol, 104, 443, 10.1097/01.AOG.0000137833.43248.79
Beral, 2005, Endometrial cancer and hormone-replacement therapy in the Million Women Study, Lancet, 365, 1543, 10.1016/S0140-6736(05)66455-0
The Writing Group for the PEPI Trial, 1996, Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, JAMA, 275, 370, 10.1001/jama.1996.03530290040035
Allen, 2010, Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition, Am J Epidemiol, 172, 1394, 10.1093/aje/kwq300
Cicinelli, 2002, Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study, Am J Obstet Gynecol, 187, 556, 10.1067/mob.2002.124941
Cicinelli, 2005, Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study, Fertil Steril, 83, 1859, 10.1016/j.fertnstert.2005.01.095
Hampton, 2005, Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women, Hum Reprod, 20, 2653, 10.1093/humrep/dei085
Suvanto-Luukkonen, 1999, The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience, Fertil Steril, 72, 161, 10.1016/S0015-0282(99)00162-4
Varila, 2001, A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy, Fertil Steril, 76, 969, 10.1016/S0015-0282(01)02846-1
Seeger, 2008, Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause?, J Steroid Biochem Mol Biol, 109, 11, 10.1016/j.jsbmb.2007.12.002
Stefanick, 2006, Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy, JAMA, 295, 1647, 10.1001/jama.295.14.1647
Chlebowski, 2010, Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women, JAMA, 304, 1684, 10.1001/jama.2010.1500
Chlebowski, 2003, Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial, JAMA, 289, 3243, 10.1001/jama.289.24.3243
Greendale, 1999, Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators, Ann Intern Med, 130, 262, 10.7326/0003-4819-130-4_Part_1-199902160-00003
Lundström, 2007, Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density, Climacteric, 10, 249, 10.1080/13697130701385805
Weiss, 2002, Hormone replacement therapy regimens and breast cancer risk (1), Obstet Gynecol, 100, 1148
Olsson, 2003, Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden, Cancer, 97, 1387, 10.1002/cncr.11205
Ross, 2000, Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin, J Natl Cancer Inst, 92, 328, 10.1093/jnci/92.4.328
Schairer, 2000, Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk, JAMA, 283, 485, 10.1001/jama.283.4.485
Li, 2003, Relationship between long durations and different regimens of hormone therapy and risk of breast cancer, JAMA, 289, 3254, 10.1001/jama.289.24.3254
Chen, 2002, Hormone replacement therapy in relation to breast cancer, JAMA, 287, 734, 10.1001/jama.287.6.734
Jick, 2009, Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer, Obstet Gynecol, 113, 74, 10.1097/AOG.0b013e31818fdde4
Kerlikowske, 2003, Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population, J Clin Oncol, 21, 4314, 10.1200/JCO.2003.05.151
Collins, 2005, Breast cancer risk with postmenopausal hormonal treatment, Hum Reprod Update, 11, 545, 10.1093/humupd/dmi028
Calle, 2009, Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype, Cancer, 115, 936, 10.1002/cncr.24101
Anderson, 2012, Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial, Lancet Oncol, 13, 476, 10.1016/S1470-2045(12)70075-X
Chlebowski, 2012, Changing concepts: menopausal hormone therapy and breast cancer, J Natl Cancer Inst, 104, 517, 10.1093/jnci/djs014
Brinton, 2005, Hormones and endometrial cancer–new data from the Million Women Study, Lancet, 365, 1517, 10.1016/S0140-6736(05)66431-8
Fournier, 2005, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int J Cancer, 114, 448, 10.1002/ijc.20710
Ravdin, 2007, The decrease in breast-cancer incidence in 2003 in the United States, N Engl J Med, 356, 1670, 10.1056/NEJMsr070105
Grady, 2002, Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II), JAMA, 288, 49, 10.1001/jama.288.1.49
Manson, 2003, Estrogen plus progestin and the risk of coronary heart disease, N Engl J Med, 349, 523, 10.1056/NEJMoa030808
Rossouw, 2007, Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause, JAMA, 297, 1465, 10.1001/jama.297.13.1465
Rosano, 2009, Cardiovascular aspects of menopausal hormone replacement therapy, Climacteric, 12, 41, 10.1080/13697130903012306
Hermsmeyer, 2008, Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity?, Nat Clin Pract Cardiovasc Med, 5, 387, 10.1038/ncpcardio1234
Writing Group for the PEPI Trial, 1995, Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial, JAMA, 273, 199, 10.1001/jama.1995.03520270033028
Rosano, 2000, Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women, J Am Coll Cardiol, 36, 2154, 10.1016/S0735-1097(00)01007-X
Mishra, 2005, Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys, J Clin Endocrinol Metab, 90, 3706, 10.1210/jc.2004-1557
Miyagawa, 1997, Ca2+ release mechanism of primate drug-induced coronary vasospasm, Am J Physiol, 272, H2645
Minshall, 1998, Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys, J Clin Endocrinol Metab, 83, 649
Hermsmeyer, 2004, Prevention of coronary hyperreactivity in pre-atherogenic menopausal rhesus monkeys by transdermal progesterone, Arteriosclerosis Thromb Vasc Biol, 24, 955, 10.1161/01.ATV.0000126372.14332.70
Wagner, 1996, The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys, Metabolism, 45, 1254, 10.1016/S0026-0495(96)90244-9
Al-Azzawi, 2006, Which progestogen is more likely to increase the risk of fatal myocardial infarction: a combination of epidemiological and trial evidence, Maturitas, 54, 154, 10.1016/j.maturitas.2005.10.004
Godsland, 2001, Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000, Fertil Steril, 75, 898, 10.1016/S0015-0282(01)01699-5
Shulman, 2002, Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women, Am J Cardiol, 89, 47E, 10.1016/S0002-9149(02)02413-X
Norris, 2008, Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/dydrogesterone and estradiol (2 mg)/trimegestone, Thromb Haemost, 100, 253, 10.1160/TH07-12-0746
Canonico, 2010, Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen, Menopause, 17, 1122, 10.1097/gme.0b013e3181e102eb
Canonico, 2010, Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study, Arterioscler Thromb Vasc Biol, 30, 340, 10.1161/ATVBAHA.109.196022
Gol, 2006, Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels, Maturitas, 53, 252, 10.1016/j.maturitas.2005.05.006
Koh, 2001, Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women, Circulation, 103, 1961, 10.1161/01.CIR.103.15.1961
Imthurn, 1997, Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate, J Clin Endocrinol Metab, 82, 388
White, 2006, Effects of a new hormone therapy, drospirenone and 17-β-estradiol, in postmenopausal women with hypertension, Hypertension, 48, 246, 10.1161/01.HYP.0000232179.60442.84
White, 2008, Effects of the hormone therapy, drospirenone and 17-β estradiol, on early morning blood pressure in postmenopausal women with hypertension, J Am Soc Hypertens, 2, 20, 10.1016/j.jash.2007.08.004
Simoncini, 2010, A review of the cardiovascular and breast actions of drospirenone in preclinical studies, Climacteric, 13, 22, 10.3109/13697130903437375
Schneider, 2009, Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations, Climacteric, 12, 445, 10.1080/13697130902780853
Canonico, 2007, Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study, Circulation, 115, 840, 10.1161/CIRCULATIONAHA.106.642280
Gomes, 2004, Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review, Arch Intern Med, 164, 1965, 10.1001/archinte.164.18.1965
Sehovic, 2010, Risk of venous thromboembolism with drospirenone in combined oral contraceptive products, Ann Pharmacother, 44, 898, 10.1345/aph.1M649
Parkin, 2011, Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database, BMJ, 342, d2139, 10.1136/bmj.d2139
Jick, 2011, Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data, BMJ, 342, d2151, 10.1136/bmj.d2151
Lidegaard, 2011, 2011 Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9, BMJ, 343, d6423, 10.1136/bmj.d6423
Tsutsui, 2008, Progesterone biosynthesis and action in the developing neuron, Endocrinology, 149, 2757, 10.1210/en.2007-1592
Singh, 2007, Progestins and neuroprotection: are all progestins created equal?, Minerva Endocrinol, 32, 95
Wright, 2007, ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury, Ann Emerg Med, 49, 391, 10.1016/j.annemergmed.2006.07.932
Xiao, 2008, Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial, Crit Care, 12, R61, 10.1186/cc6887
Hu, 2009, Exogenous progesterone: a potential therapeutic candidate in CNS injury and neurodegeneration, Curr Med Chem, 16, 1418, 10.2174/092986709787846523
Stein, 2010, Progesterone in the clinical treatment of acute traumatic brain injury, Expert Opin Investig Drugs, 19, 847, 10.1517/13543784.2010.489549
Schumacher, 2008, Progesterone and progestins: neuroprotection and myelin repair, Curr Opin Pharmacol, 8, 740, 10.1016/j.coph.2008.10.002
Ciriza, 2006, Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective, J Neurobiol, 66, 916, 10.1002/neu.20293
Nilsen, 2002, Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate, Endocrinology, 143, 205, 10.1210/endo.143.1.8582
Nilsen, 2003, Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling, Proc Natl Acad Sci USA, 100, 10506, 10.1073/pnas.1334098100
Nilsen, 2006, Medroxyprogesterone acetate exacerbates glutamate excitotoxicity, Gynecol Endocrinol, 22, 355, 10.1080/09513590600863337
Wright, 2008, Effects of medroxyprogesterone acetate on cerebral oedema and spatial learning performance after traumatic brain injury in rats, Brain Inj, 22, 107, 10.1080/02699050701867399
Resnick, 2009, Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study, Neurology, 72, 135, 10.1212/01.wnl.0000339037.76336.cf
Schumacher, 2007, Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system, Endocr Rev, 28, 387, 10.1210/er.2006-0050
Nelson HD 2002 Hormone replacement therapy and osteoporosis. Systematic Evidence Reviews No. 12. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=es12
Dören, 2003, Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis, Hum Reprod, 18, 1737, 10.1093/humrep/deg315
Abdalla, 1985, Prevention of bone mineral loss in postmenopausal women by norethisterone, Obstet Gynecol, 66, 789
Gallagher, 1991, Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen, Am J Med, 90, 171, 10.1016/0002-9343(91)90538-9
Prior, 1994, Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances, Am J Med, 96, 521, 10.1016/0002-9343(94)90092-2
Prior, 2006, Unsuccessful attempt to demonstrate progesterone's bone formation actions, Am J Obstet Gynecol, 194, 1502, 10.1016/j.ajog.2005.10.201
Hammond, 2002, Access of reproductive steroids to target tissues, Obstet Gynecol Clin North Am, 29, 411, 10.1016/S0889-8545(02)00008-6
Sitruk-Ware, 2007, Routes of delivery for progesterone and progestogens, Maturitas, 57, 77, 10.1016/j.maturitas.2007.02.015
Sitruk-Ware, 2005, Pharmacology of different progestogens: the special case of drospirenone, Climacteric, 8, 4, 10.1080/13697130500330382
Sitruk-Ware, 2006, Contraception: an international perspective, Contraception, 73, 215, 10.1016/j.contraception.2005.08.019
Charles, 2010, Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events, Horm Cancer, 1, 167, 10.1007/s12672-010-0023-9
Shang, 2002, Molecular determinants for the tissue specificity of SERMs, Science, 295, 2465, 10.1126/science.1068537
Kurman, 1985, The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients, Cancer, 56, 403, 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X
Africander D 2010 Comparative study of the molecular mechanism of action of the synthetic progestins, MPA and norethisterone acetate. PhD thesis, University of Stellenbosch, South Africa